Cancer Diagnostics – News and Features

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been created.

Researchers explore how established agricultural pest management strategies could be adapted to address cancer therapy. The pioneering method opens new possibilities for controlling drug resistance and improving patient survival.

Patho-DBiT, a new pathology tool from Yale, uses DNA barcoding to spatially map RNA and proteins in tumor tissues. It provides unprecedented molecular insights, aiding targeted therapies and cancer biology research.

A study reveals that 3% of normal breast cells in healthy women have chromosomal abnormalities linked to invasive breast cancer, challenging current cancer detection methods. Aneuploid cells accumulate with age and mimic invasive cancer profiles.

Precision diagnostics for diseases that affect the brain and other organs brought closer by new ability to exclusively access contents of organ-derived extracellular vesicles in blood.

The INAVO120 study reveals that the three-drug therapy inavolisib, palbociclib and fulvestrant significantly delays cancer progression in PIK3CA-mutated breast cancer. The therapy has received FDA approval and shows promise as a new standard of care.

An international team has developed a new imaging method that analyzes cancer cells and their surrounding tissue at a single-cell level. This innovative approach identifies distinct patient groups based on prognosis.

A team at The University of Texas at El Paso has developed a microfluidic device that can quickly and affordably detect colorectal and prostate cancer. This innovative biochip eliminates the need for expensive equipment.

An AI model designed to detect skin cancer outperformed existing methods in a new study.

An experimental blood test detects early-stage pancreatic cancer more effectively than other available tests. The findings pave are an important step toward approval as a potential diagnostic method for pancreatic cancer.